One-year surveillance of eskape pathogens in an intensive care unit of monterrey, Mexico

Chemotherapy

Volumn 58, Issue 6, 2013, Pages 475-481

  Llaca Díaz, Jorge Martín ^a   Mendoza Olazarán, Soraya ^b   Camacho Ortiz, Adrian ^a   Flores, Samantha ^b   Garza González, Elvira ^a,b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b Medicina UANL   (Mexico)

Author keywords

Extended spectrum lactamases; Intensive care unit; Multidrug resistance; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MEXICO; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TERTIARY HEALTH CARE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS; MEXICO; MICROBIAL SENSITIVITY TESTS; TERTIARY CARE CENTERS;

EID: 84875679172     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000346352     Document Type: Article

References (35)

1. Gould I: The epidemiology of antibiotic resistance. Int J Antimicrob Agents 2008; 32(suppl 1):S2-S9.
2. Wienke M, Pfeifer Y, Weissgerber P, Marschal M, Autenrieth IB, Grobner S: In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coliand Klebsiella pneumoniaeisolates from a university hospital in South-Western Germany. Chemotherapy 2012; 58: 241-248.
3. Koksal F, Ak K, Kucukbasmaci O, Samasti M: Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamaseproducingEscherichia coli and Klebsiella pneumoniaeisolated from blood cultures in an Istanbul university hospital. Chemotherapy 2009; 55: 293-297.
4. Bassetti M, Ginocchio F, Mikulska M: New treatment options against Gram-negative organisms. Crit Care 2011; 15: 215.
5. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008; 197: 1079-1081.
6. Rice LB: Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 2010; 31(suppl 1):S7-S10.
7. Slama T: Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008; 12(suppl 4):S4.
8. Kunz AN, Brook I: Emerging resistant Gramnegative aerobic bacilli in hospital-acquired infections. Chemotherapy 2010; 56: 492-500.
9. Peleg A, Seifert H, Paterson D: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
10. Rhomberg P, Jones R, Sader H, Fritsche T: Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test InformationCollection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis 2004; 49: 273-281.
11. Garza-Gonzalez E, Llaca-Diaz JM, Bosques- Padilla FJ, Gonzalez GM: Prevalence ofmultidrug- resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy 2010; 56: 275-279.
12. Paterson D, Bonomo R: Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
13. Hawkey P: Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol 2008; 153(suppl 1):S406-S413.
14. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, Miyashiro D, Quinn JP, Weinstein RA, Trenholme GM: Ceftazidime- resistantKlebsiella pneumoniae and Escherichia colibloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-536.
15. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Investigators ABCsAM: Invasive methicillinresistantStaphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771.
16. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch AJ, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Kelmere AM, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H, Group BS: Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureusbloodstream infections. Antimicrob Agents Chemother 2011; 55: 1598-1605.
17. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, Klare I, Kristinsson KG, Leclercq R, Lester CH, Lillie M, Novais C, Olsson-Liljequist B, Peixe LVSadowy E, Simonsen GS, Top J, Vuopio- Varkila J, Willems RJ, Witte W, Woodford N: Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008; 13: 19046.
18. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN: Antimicrobial resistance and molecular epidemiology of vancomycin- resistant enterococci from North America and Europe: a report from the sentry antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007; 58: 163-170.
19. Stamm W, Grayson ML, Nicolle L, Powell M: WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva, World Health Organization, 2001.
20. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement, M100-S20. Wayne, Clinical and Laboratory Standards Institute, 2010.
21. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC: Characterization of glycopeptide- resistant enterococci from U.S. Hospitals. Antimicrob Agents Chemother 1993; 37: 2311-2317.
22. Ramphal R: Importance of adequate initial antimicrobial therapy. Chemotherapy 2005; 51: 171-176.
23. Cerqueira GM, Peleg AY: Insights into Acinetobacter baumanniipathogenicity. IUBMB Life 2011; 63: 1055-1060.
24. Al-Tawfiq J, Mohandhas T: Prevalence of antimicrobial resistance inAcinetobacter calcoaceticus- baumannii complex in a Saudi Arabian hospital. Infect Control Hosp Epidemiol 2007; 28: 870-872.
25. Gales A, Jones R, Forward K, Linares J, Sader H, Verhoef J: Emerging importance of multidrug- resistantAcinetobacter species and Stenotrophomonas maltophiliaas pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32(suppl 2):S104-S113.
26. Seifert H, Dowzicky M: A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the tigecycline evaluation and surveillance trial (2004- 2007). Chemotherapy 2009; 55: 241-252.
27. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Kugler KC, Beach ML, Sader HS: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY participants group. Int J Antimicrob Agents 2000; 13: 257-271.
28. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW: Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli andKlebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574- 4581. 10.1159/000346352 481
29. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T: Predictors of mortality in patients with bloodstream infections caused by extended- spectrum-beta-lactamase-producingEnterobacteriaceae : importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-1994.
30. Muro S, Garza-Gonzalez E, Camacho-Ortiz A, Gonzalez GM, Llaca-Diaz JM, Bosques F, Rositas F: Risk factors associated with extendedspectrum â-lactamase-producing Enterobacteriaceaenosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis. Chemotherapy 2012; 58: 217-224.
31. Garza-Gonzalez E, Mendoza Ibarra SI, Llaca- Diaz JM, Gonzalez GM: Molecular characterization and antimicrobial susceptibility of extended- spectrum â-lactamase-producingEnterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. J Med Microbiol 2011; 60: 84-90.
32. Stefani S, Varaldo P: Epidemiology of methicillin- resistant staphylococci in Europe. Clin Microbiol Infect 2003; 9: 1179-1186.
33. Alp E, Klaassen CH, Doganay M, Altoparlak U, Aydin K, Engin A, Kuzucu C, Ozakin C, Ozinel MA, Turhan O, Voss A: MRSA genotypes in Turkey: persistence over 10 years of a single clone of ST239. J Infect 2009; 58: 433-438.
34. Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A: Mobile genetic elements and their contribution to the emergence of antimicrobial resistantEnterococcus faecalis and Enterococcus faecium. Clin Microbiol Infect 2010; 16: 541-554.
35. Cuellar-Rodriguez J, Galindo-Fraga A, Guevara V, Perez-Jimenez C, Espinosa-Aguilar L, Rolon AL, Hernandez-Cruz A, Lopez-Jacome E, Bobadilla-del-Valle M, Martinez-Gamboa A, Ponce-de-Leon A, Sifuentes-Osornio J: Vancomycin-resistant enterococci, Mexico City. Emerg Infect Dis 2007; 13: 798-799.